Incentives of Registered Business Enterprises (RBEs) under the CREATE MORE Act
Tax NotesLast 27 November 2024, RA No. 12066, otherwise known as the CREATE MORE Act, took effect after its publication.
The Bureau of Internal Revenue (BIR) has suspended all audit and related field operations concerning the examination and verification of taxpayers, including their books of accounts, records, and other transactions from December 16, 2024, to January 12, 2025. During this period, the issuance of audit orders and investigations into taxpayers’ internal revenue tax liabilities will be put on hold, except for the following cases:
In addition, revenue collection efforts, including the issuance of assessment notices, warrants, and seizure notices will continue as necessary. Nevertheless, taxpayers may voluntarily settle deficiency taxes without requiring BIR approval.
Please be guided accordingly.
Source:
P&A Grant Thornton
Certified Public Accountants
P&A Grant Thornton is the Philippine member firm of Grant Thornton International Ltd.
As published in SunStar Cebu, dated 31 December 2024
Last 27 November 2024, RA No. 12066, otherwise known as the CREATE MORE Act, took effect after its publication.
Under the Corporate Recovery and Tax Incentives for Enterprises (CREATE) Act, certain health products, such as drugs for noncommunicable diseases, were exempted from Value Added Tax (VAT). Last December 3, 2024, an update to the list of VAT-exempt medicines was issued by the Bureau of Internal Revenue (BIR), in coordination with the Food and Drug Administration (FDA).
On November 15, 2024, the BIR issued Revenue Memorandum Circular No. 123-2024 to clarify the validity of the issuance of the Certificate of Tax Exemption (CTE) to certain tax-exempt corporations.